GlassScriptPhysician profile
Jeremy David Waldram
NPI 1396972311
$1,726.99
in general payments reported to CMS, 2019-2025
23 companies · $224 in 2025
The $224 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $52.50 · 2021: $234 · 2022: $510 · 2023: $393 · 2024: $314 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $391.52 | 2020-2024 | Tezspire, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $303.13 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $131.32 | 2021-2025 | Dupixent |
| Genentech USA, INC. | $112.96 | 2021-2023 | Xolair |
| Kaleo, INC. | $97.76 | 2021-2023 | Auvi-Q |
| Grifols USA, LLC | $94.38 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.59 | 2021-2024 | Eohilia, Gattex |
| Novartis Pharmaceuticals Corporation | $78.07 | 2022-2025 | |
| Pharming Healthcare, INC. | $74.70 | 2022-2024 | Ruconest |
| Csl Behring | $42.63 | 2020-2024 | Hizentra |
| Blueprint Medicines Corporation | $41.12 | 2023 | Ayvakit |
| Horizon Therapeutics Plc | $37.42 | 2021 | |
| Amgen INC. | $35.18 | 2022-2025 | Tezspire |
| Verona Pharma, INC. | $32.02 | 2025 | Ohtuvayre |
| Leo Pharma INC. | $24.61 | 2024 | Adbry |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| X4 Pharmaceuticals, INC. | $21.57 | 2024 | Xolremdi |
| Medtronic, INC. | $19.65 | 2022 | |
| Cycle Pharmaceuticals INC | $19.39 | 2024 | Sajazir |
| Exact Sciences Corporation | $17.26 | 2024 | |
| Incyte Corporation | $15.93 | 2022 | |
| Aimmune Therapeutics, INC. | $15.92 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $15.76 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $12.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Waldram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.